Stabilization of vulnerable plaque in the ACS patient: evidence from HUYGENS studies

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Medical Imaging

Background:

• Atherosclerosis was considered irreversible, but statins showed plaque stabilization and reduction.
• PCSK9 inhibitors, alongside statins, offer enhanced LDL-C lowering and cardiovascular event reduction.

Purpose of the Study:

• To evaluate the effect of PCSK9 inhibitors on atherosclerotic plaque phenotype beyond burden reduction.
• To assess changes in plaque characteristics, including fibrous cap thickness, lipid content, and inflammatory markers.

Main Methods:

• Analysis of intra-coronary imaging data (likely IVUS) from the HUYGENS study.
• Assessment of changes in plaque composition and morphology in patients treated with PCSK9 inhibitors and statins.

Main Results:

• PCSK9 inhibitors demonstrated not only plaque stabilization/reduction but also favorable changes in plaque phenotype.
• Observed improvements include increased fibrous cap thickness (FCT), decreased maximum lipid arc, and reduced macrophage infiltration.

Conclusions:

• PCSK9 inhibitors positively impact atherosclerotic plaque phenotype, suggesting a potential to regress high-risk plaque features.
• Further research is warranted to determine the clinical significance of these plaque phenotype modifications in reducing cardiovascular events.